Management of infrapopliteal peripheral arterial occlusive disease

Current Treatment Options in Cardiovascular Medicine

Volumn 14, Issue 2, 2012, Pages 136-148

  Gasper, Warren J ^a   Runge, Sara J ^a   Owens, Christopher D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angioplasty; Critical limb ischemia; Infrapopliteal arteries; Lower extremity bypass; Peripheral arterial disease; Stent; Tibial arteries

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DACRON; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; POLITEF; RAPAMYCIN; SCATTER FACTOR; THIAZIDE DIURETIC AGENT; VASCULOTROPIN;

ARTICLE; BELOW KNEE AMPUTATION; BYPASS SURGERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLAUDICATION; CONVALESCENCE; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DRUG ELUTING STENT; EVENT FREE SURVIVAL; GOLD STANDARD; HEALTH CARE COST; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; INFRAPOPLITEAL PERIPHERAL ARTERIAL OCCLUSIVE DISEASE; INTERMETHOD COMPARISON; INTERMITTENT CLAUDICATION; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; INTERVENTION STUDY; KINESIOTHERAPY; LEG REVASCULARIZATION; LIFESTYLE MODIFICATION; LIMB SALVAGE; LUMBAR SYMPATHECTOMY; OVERALL SURVIVAL; PATIENT SAFETY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; POSTOPERATIVE INFECTION; QUALITY OF LIFE; RISK REDUCTION; SPINAL CORD STIMULATION; STROKE; SURGICAL INFECTION; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; WOUND CARE;

EID: 85027937563     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-012-0164-y     Document Type: Article

References (54)

1. Norgren L, Hiatt W, Dormandy J, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45:S5-S67. (Pubitemid 46151680)
2. Gray BH, Grant AA, Kalbaugh CA, et al. The impact of isolated tibial disease on outcomes in the critical limb ischemic population. Ann Vasc Surg. 2010;24:349-59.
3. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the managementofpatients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the american association for vascular surgery/society for vascular surgery, society for cardiovascular angiography and interventions, society for vascular medicine and biology, society of interventional radiology, and the ACC/AHA task force on practice guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease): endorsed by the american association of cardiovascular and pulmonary rehabilitation; national heart, lung, and blood institute; society for vascular nursing; TransAtlantic inter-society consensus; and vascular disease foundation. Circulation. 2006;113:e463-654.
4. Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011, 124:2020-45. The 2011 update to the 2005 ACC/AHA PAD Practice guidelines contains updates to diagnostic methods, smoking cessation, antiplatelet, and CLI recommendations.
5. Hamburg NM, Balady GJ. Exercise rehabilitation in peripheral artery disease: functional impact and mechanisms of benefits. Circulation. 2011;123:87-97.
6. Grundy SM. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation. 2004;110:227-39. (Pubitemid 38924592)
7. Momsen AH, Jensen MB, Norager CB, et al. Drug therapy for improving walking distance in intermittent claudication: a systematic review and metaanalysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg. 2009;38:463-74.
8. Lane DA, Lip GY. Treatment of hypertension in peripheral arterial disease. Cochrane database of systematic reviews 2009:CD003075.
9. Diehm C, Pittrow D, Lawall H. Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication. J Hypertens. 2011;29:1448-56.
10. Espinola-Klein C, Weisser G, Jagodzinski A, et al. beta-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension. 2011;58:148-54.
11. Mohler ER. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108:1481-6.
12. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207.
13. Goodney PP, Beck AW, Nagle J, et al. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg. 2009;50:54-60.
14. Sadek M, Ellozy SH, Turnbull IC, et al. Improved outcomes are associated with multilevel endovascular intervention involving the tibial vessels compared with isolated tibial intervention. J Vasc Surg. 2009;49:638-44.
15. Fernandez N, McEnaney R, Marone LK, et al. Predictors of failure and success of tibial interventions for critical limb ischemia. J Vasc Surg 2010:1-9.
16. Giles KA, Pomposelli FB, Hamdan AD, et al. Infrapopliteal angioplasty for critical limb ischemia: relation of TransAtlantic InterSociety consensus class to outcome in 176 limbs. J Vasc Surg. 2008;48:128-36.
17. Romiti M, Albers M, Brochado-Neto FC, et al. Metaanalysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 2008;47:975-81. e1.
18. Conrad MF, Kang J, Cambria RP, et al. Infrapopliteal balloon angioplasty for the treatment of chronic occlusive disease. J Vasc Surg. 2009;50:799-805.e4.
19. Donas KP, Torsello G, Schwindt A, et al. Below knee bare nitinol stent placement in high-risk patients with critical limb ischemia is still durable after 24 months of follow-up. J Vasc Surg. 2010;52:356-61.
20. Siablis D, Karnabatidis D, Katsanos K, et al. Infrapopliteal application of paclitaxel-eluting stents for critical limb ischemia: midterm angiographic and clinical results. J Vasc Interv Radiol. 2007;18:1351-61. (Pubitemid 350010920)
21. Siablis D, Karnabatidis D, Katsanos K, et al. Infrapopliteal application of sirolimus-eluting versus bare metal stents for critical limb ischemia: analysis of long-term angiographic and clinical outcome. J Vasc Interv Radiol. 2009;20:1141-50.
22. Randon C, Jacobs B, De Ryck F, Vermassen F. Angioplasty or primary stenting for infrapopliteal lesions: results of a prospective randomized trial. Cardiovasc Intervent Radiol. 2010;33:260-9.
23. Rastan A, Tepe G, Krankenberg H, et al. Sirolimuseluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a doubleblind, multi-centre, randomized clinical trial. Eur Heart J. 2011;32:2274-81.
24. Stoner MC, deFreitas DJ, Phade SV, et al. Mid-term results with laser atherectomy in the treatment of infrainguinal occlusive disease. J Vasc Surg. 2007;46:289-95.
25. Zeller T, Sixt S, Schwarzwälder U, et al. Two-year results after directional atherectomy of infrapopliteal arteries with the SilverHawk device. J Endovasc Ther. 2007;14:232-40. (Pubitemid 46776122)
26. Bosiers M, Deloose K, Vermassen F, et al. The use of the cryoplasty technique in the treatment of infrapopliteal lesions for critical limb ischemia patients in a routine hospital setting: one-year outcome of the cryoplasty CLIMB registry. J Cardiovasc Surg (Torino). 2010;51:193-202.
27. Das TS, McNamara T, Gray B, et al. Primary cryoplasty therapy provides durable support for limb salvage in critical limb ischemia patients with infrapopliteal lesions: 12-month follow-up results from the BTK Chill Trial. J Endovasc Ther. 2009;16:II19-30.
28. Schmidt A, Piorkowski M, Werner M, et al. First experience with drug-eluting balloons in infrapopliteal arteries restenosis rate and clinical outcome. J Am Coll Cardiol. 2011;58:1105-9.
29. Yeh K-H, Tsai Y-J, Huang H-L, et al. Dual vascular access for critical limb ischemia: immediate and follow-up results. Catheter Cardiovasc Interv. 2011;77:296-302.
30. Bradbury AW, Adam DJ, Bell J, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: an intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy. J Vasc Surg. 2010;51:5S-17S.
31. Bradbury AW, Adam DJ, Bell J, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Analysis of amputation free and overall survival by treatment received. J Vasc Surg 2010, 51:18S-31S. This article presents the long-term results of a by-treatmentreceived analysis of the BASIL trial.
32. Forbes JF, Adam DJ, Bell J, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: health-related quality of life outcomes, resource utilization, and cost-effectiveness analysis. J Vasc Surg. 2010;51:43S-51S.
33. Conte MS, Geraghty PJ, Bradbury AW, et al. Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg 2009, 50:1462-73.e3. The article discusses suggested objective performance goals for device trials that target CLI.
34. Schanzer A, Hevelone N, Owens CD, et al. Technical factors affecting autogenous vein graft failure: observations from a large multicenter trial. J Vasc Surg. 2007;46:1180-90. discussion 90. (Pubitemid 350267083)
35. Reed AB, Conte MS, Belkin M, et al. Usefulness of autogenous bypass grafts originating distal to the groin. J Vasc Surg. 2002;35:48-54. discussion, -5. (Pubitemid 44725770)
36. Albers M, Battistella VM, Romiti M, et al. Metaanalysis of polytetrafluoroethylene bypass grafts to infrapopliteal arteries. J Vasc Surg. 2003;37:1263-9. (Pubitemid 41123104)
37. Randon C, Jacobs B, De Ryck F, et al. Fifteen years of infrapopliteal arterial reconstructions with cryopreserved venous allografts for limb salvage. J Vasc Surg. 2010;51:869-77.
38. Sultan S, Hamada N, Soylu E, et al. Sequential compression biomechanical device in patients with critical limb ischemia and nonreconstructible peripheral vascular disease. J Vasc Surg. 2011;54:440-7.
39. Kavros SJ, Delis KT, Turner NS, et al. Improving limb salvage in critical ischemia with intermittent pneumatic compression: a controlled study with 18-month follow-up. J Vasc Surg. 2008;47:543-9. (Pubitemid 351258280)
40. Ubbink DT, Vermeulen H. Spinal cord stimulation for critical leg ischemia: a review of effectiveness and optimal patient selection. J Pain Symptom Manage. 2006;31:S30-5. (Pubitemid 44389548)
41. Klomp HM, Steyerberg EW, van Urk H, Habbema JD. Spinal cord stimulation is not cost-effective for non-surgical management of critical limb ischaemia. Eur J Vasc Endovasc Surg. 2006;31:500-8.
42. Coventry BJ, Walsh JA. Cutaneous innervation in man before and after lumbar sympathectomy: evidence for interruption of both sensory and vasomotor nerve fibres. ANZ J Surg. 2003;73:14-8. (Pubitemid 36237765)
43. Nemes R, Surlin V, Chiutu L, et al. Retroperitoneoscopic lumbar sympathectomy: prospective study upon a series of 50 consecutive patients. Surg Endosc. 2011;25:3066-70.
44. Investigators O, Bot AI, Bosiers M. AMS INSIGHT-absorbable metal stent implantation for treatment of below-the-knee critical limb ischemia: 6-month analysis. Cardiovasc Intervent Radiol. 2008;32:424-35.
45. Powell RJ, Goodney P, Mendelsohn FO, et al. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial. J Vasc Surg. 2010;52:1525-30.
46. Rajagopalan S, Mohler 3rd ER, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003;108:1933-8. (Pubitemid 37296537)
47. Kusumanto YH, van Weel V, Mulder NH, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gen Ther. 2006;17:683-91. (Pubitemid 43970708)
48. Amann B, Luedemann C, Ratei R, Schmidt-Lucke JA. Autologous bone marrow cell transplantation increases leg perfusion and reduces amputations in patients with advanced critical limb ischemia due to peripheral artery disease. Cell Transplant. 2009;18:371-80.
49. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bonemarrow cells: a pilot study and a randomised controlled trial. Lancet. 2002;360:427-35.
50. Powell RJ, Comerota AJ, Berceli SA, et al. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia. J Vasc Surg. 2011;54:1032-41.
51. ClinicalTrials.gov. Available at: http://clinicaltrials.gov/. Accessed August 2011.
52. Martens JM, Knippenberg B, Vos JA, et al. Update on PADI trial: percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia. J Vasc Surg. 2009;50:687-9.
53. Bosiers M, Deloose K, Callaert J, et al. Drug-eluting stents below the knee. J Cardiovasc Surg (Torino). 2011;52:231-4.
54. Zeller T, Schmitmeier S, Tepe G, Rastan A. Drugcoated balloons in the lower limb. J Cardiovasc Surg (Torino). 2011;52:235-43.